00978nam0-22003131i-450-99000555090040332120090717094908.090-04-04546-5000555090FED01000555090(Aleph)000555090FED0100055509019990604d1976----km-y0itay50------baengy-------001yyChalcis-in-Euboea, iron and Chalcidians abroadChalcidian studies IIIby S.C. BakhuizenLeidenE.J. Brill1976100 p.27 cmStudies of the Dutch Archaeological and Historical Society5938.422itaBakhuizen,S. C.154428ITUNINARICAUNIMARCBK990005550900403321ARCH, G 197 8ARCH. 17657FLFBC938.4 BAK 1ANT.G.R. 2635FLFBCFLFBCChalcis-in-Euboea, iron and Chalcidians abroad175613UNINA00856cam0-22003011i-450-99000783923040332120070910094425.00-333-96901-4000783923FED01000783923(Aleph)000783923FED0100078392320031120d2003----km-y0itay50------baengUSy-------001yyLanguage and power in courta linguistic analysis of the O.J. Simpson trialJanet CotterillNew YorkPalgrave Macmillan2003Simpson, O. J.345.7321itaCotterill,Janet280718ITUNINARICAUNIMARCBK990007839230403321XV Ib 49140656FSPBCFSPBCLanguage and power in court672246UNINA04747nam 2200673Ia 450 991045507280332120200520144314.01-282-36844-397866123684480-470-46636-70-470-46635-9(CKB)1000000000822085(EBL)469409(OCoLC)609848053(SSID)ssj0000291823(PQKBManifestationID)11238666(PQKBTitleCode)TC0000291823(PQKBWorkID)10253911(PQKB)10289536(MiAaPQ)EBC469409(Au-PeEL)EBL469409(CaPaEBR)ebr10346509(CaONFJC)MIL236844(EXLCZ)99100000000082208520090210d2009 uy 0engur|n|---|||||txtccrClinical trials handbook[electronic resource] /edited by Shayne Cox GadHoboken, NJ Wileyc20091 online resource (1247 p.)Pharmaceutical Development Series ;v.8Description based upon print version of record.0-471-21388-8 Includes bibliographical references and index.Clinical Trials Handbook; Contents; Preface; Contributors; 1 Introduction to Clinical Trials; 2 Regulatory Requirements for Investigational New Drug; 3 Preclinical Assessment of Safety in Human Subjects; 4 Predicting Human Adverse Drug Reactions from Nonclinical Safety Studies; 5.1 History of Clinical Trial Development and the Pharmaceutical Industry; 5.2 Adaptive Research; 6 Organization and Planning; 7 Process of Data Management; 8 Clinical Trials Data Management; 9.1 Clinical Trials and the Food and Drug Administration; 9.2 Phase I Clinical Trials; 9.3 Phase II Clinical Trials9.4 Designing and Conducting Phase III Studies9.5 Phase IV: Postmarketing Trials; 9.6 Phase IV and Postmarketing Clinical Trials; 9.7 Regulatory Approval; 9.8 New Paradigm for Analyzing Adverse Drug Events; 10.1 Clinical Trials in Interventional Cardiology: Focus on XIENCE Drug-Eluting Stent; 10.2 Clinical Trials Involving Oral Diseases; 10.3 Dermatology Clinical Trials; 10.4 Emergency Clinical Trials; 10.5 Gastroenterology; 10.6 Gynecology Randomized Control Trials; 10.7 Special Population Studies (Healthy Patient Studies); 10.8 Musculoskeletal Disorders; 10.9 Oncology10.10 Pharmacological Treatment Options for Nonexudative and Exudative Age-Related Macular Degeneration10.11 Paediatrics; 10.12 Clinical Trials in Dementia; 10.13 Clinical Trials in Urology; 10.14 Clinical Trials on Cognitive Drugs; 10.15 Bridging Studies in Pharmaceutical Safety Assessment; 10.16 Brief History of Clinical Trials on Viral Vaccines; 11 Methods of Randomization; 12 Randomized Controlled Trials; 13 Cross-Over Designs; 14.1 Biomarkers; 14.2 Biomarkers in Clinical Drug Development: Parallel Analysis of Alzheimer Disease and Multiple Sclerosis; 15 Review Boards16 Size of Clinical Trials17 Blinding and Placebo; 18 Pharmacology; 19 Modeling and Simulation in Clinical Drug Development; 20 Monitoring; 21 Inference Following Sequential Clinical Trials; 22 Statistical Methods for Analysis of Clinical Trials; 23 Explanatory and Pragmatic Clinical Trials; 24.1 Ethics of Clinical Research in Durg Trials; 24.2 Ethical Issues in Clinical Research; 25 Regulations; 26 Future Challenges in Design and Ethics of Clinical Trials; 27 Proof-of-Principle/Proof-of-Concept Trials in Drug Development; IndexBest practices for conducting effective and safe clinical trials Clinical trials are arguably the most important steps in proving drug effectiveness and safety for public use. They require intensive planning and organization and involve a wide range of disciplines: data management, biostatistics, pharmacology, toxicology, modeling and simulation, regulatory monitoring, ethics, and particular issues for given disease areas. Clinical Trials Handbook provides a comprehensive and thorough reference on the basics and practices of clinical trials. With contributions from a range ofPharmaceutical Development SeriesDrugsTestingHandbooks, manuals, etcClinical trialsHandbooks, manuals, etcElectronic books.DrugsTestingClinical trials615.1615.580724615/.1Gad Shayne C.1948-96171MiAaPQMiAaPQMiAaPQBOOK9910455072803321Clinical trials handbook2168020UNINA01627nam 2200409 a 450 991069305070332120041006090146.0(CKB)5470000002358998(OCoLC)56631562ocm56631562(OCoLC)995470000002358998(EXLCZ)99547000000235899820041006d2004 ua 0engurmn||||||txtrdacontentcrdamediacrrdacarrierFood Stamp Program[electronic resource] Farm Bill options ease administrative burden, but opportunities exist to streamline participant reporting rules among programs : report to the Committee on Agriculture, Nutrition, and Forestry, U.S. Senate[Washington, D.C.] :U.S. Government Accountability Office,[2004]Title from title screen (viewed on Oct. 5, 2004)."September 2004."Paper version available from: U.S. Government Accountability Office, 441 G St., NW, Rm. LM, Washington, D.C. 20548."GAO-04-916."Includes bibliographical references.Food Stamp Program Food stampsUnited StatesEvaluationPoorServices forUnited StatesEvaluationFood stampsEvaluation.PoorServices forEvaluation.United States.Congress.Senate.Committee on Agriculture, Nutrition, and Forestry.GPOGPOBOOK9910693050703321Food Stamp Program3426048UNINA02761nam 2200613 a 450 991078121450332120230725050530.01-4529-4589-60-8166-7653-4(CKB)2550000000040001(EBL)730141(OCoLC)741492676(SSID)ssj0000522708(PQKBManifestationID)11913751(PQKBTitleCode)TC0000522708(PQKBWorkID)10538572(PQKB)10330100(StDuBDS)EDZ0001178013(MiAaPQ)EBC730141(MdBmJHUP)muse29852(Au-PeEL)EBL730141(CaPaEBR)ebr10482230(CaONFJC)MIL525794(EXLCZ)99255000000004000120101210d2011 uy 0engur|n|---|||||txtccrFree Burma[electronic resource] transnational legal action and corporate accountability /John G. DaleMinneapolis University of Minnesota Pressc20111 online resource (328 p.)Description based upon print version of record.0-8166-4647-3 0-8166-4646-5 Includes bibliographical references and index.Burma's struggle for democracy and human rights before 1988 -- Locating power in the free Burma movement -- Free Burma laws : legislating transnational sanctions -- Corporate "death penalty" : executing charter revocation -- Alien tort claims : adjudicating human rights abuses abroad.When the military's ruling party violently quashed Burma's pro-democracy movement, diplomatic condemnation quickly followed--to little effect. But when Burma's activists began linking the movement to others around the world, the result was dramatically different. This book is the first to explain how Burma's pro-democracy movement became a transnational social movement for human rights. Through the experience of the Free Burma movement, John G. Dale demonstrates how social movements create and appropriate legal mechanisms for generating new transnational political opportunities. He presents thUnited StatesForeign relationsLaw and legislationBurmaInternational statusBurmaPolitics and government1988-United StatesForeign relationsBurmaBurmaForeign relationsUnited States341.5/82Dale John G1519271MiAaPQMiAaPQMiAaPQBOOK9910781214503321Free Burma3757292UNINA$52.5007/24/2015Dis